ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of RevID with a 400-bed, Oracle Health-EHR based health system with facilities in Western Texas. The deal was closed in partnership with Oracle Health.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation enables hospitals to capture 100% of earned revenue by eliminating charge capture gaps and accelerates cash flow by ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide. Enabled by seamless integration with Oracle Health’s Soarian billing platform, RevID positions health systems to enhance financial operations by automating and optimizing charge reconciliation processes for greater accuracy and efficiency.
“Texas is home to some of the nation’s most forward-thinking healthcare providers, and is an ideal market for continued expansion,” stated Ben Stilwill, Chief Executive Officer. “Our growing partnership with Oracle Health strengthens our ability to deliver pre-bill solutions that seamlessly integrate with leading EHR platforms. We look forward to extending our footprint across Texas and beyond.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
Last Trade: | US$2.33 |
Daily Change: | 0.02 0.87 |
Daily Volume: | 7,688 |
Market Cap: | US$9.950M |
January 22, 2025 December 16, 2024 October 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load